These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 17656424)

  • 1. Schizophrenia, antipsychotics and metabolic disease.
    Reynolds GP
    J Psychopharmacol; 2007 Jun; 21(4):355-6. PubMed ID: 17656424
    [No Abstract]   [Full Text] [Related]  

  • 2. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia.
    Barnett AH; Mackin P; Chaudhry I; Farooqi A; Gadsby R; Heald A; Hill J; Millar H; Peveler R; Rees A; Singh V; Taylor D; Vora J; Jones PB
    J Psychopharmacol; 2007 Jun; 21(4):357-73. PubMed ID: 17656425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic complications of schizophrenia and antipsychotic medications--an updated review.
    Yogaratnam J; Biswas N; Vadivel R; Jacob R
    East Asian Arch Psychiatry; 2013 Mar; 23(1):21-8. PubMed ID: 23535629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.
    Casey DE; Haupt DW; Newcomer JW; Henderson DC; Sernyak MJ; Davidson M; Lindenmayer JP; Manoukian SV; Banerji MA; Lebovitz HE; Hennekens CH
    J Clin Psychiatry; 2004; 65 Suppl 7():4-18; quiz 19-20. PubMed ID: 15151456
    [No Abstract]   [Full Text] [Related]  

  • 5. [Schizophrenia and antipsychotics associated with the metabolic syndrome. An overview].
    Scheepers-Hoeks AM; Wessels-Basten SJ; Scherders MJ; Bravenboer B; Loonen AJ; Kleppe RT; Grouls RJ
    Tijdschr Psychiatr; 2008; 50(10):645-54. PubMed ID: 18951343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
    Stahl SM; Mignon L; Meyer JM
    Acta Psychiatr Scand; 2009 Mar; 119(3):171-9. PubMed ID: 19178394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs.
    Newcomer JW
    J Clin Psychiatry; 2004; 65 Suppl 18():36-46. PubMed ID: 15600383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Metabolic risk during antipsychotic treatment in patients with schizophrenia].
    Rzewuska M
    Psychiatr Pol; 2007; 41(4):457-72. PubMed ID: 18046977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of schizophrenia with obesity, metabolic, and endocrinological disorders.
    Monteleone P; Martiadis V; Maj M
    Psychiatr Clin North Am; 2009 Dec; 32(4):775-94. PubMed ID: 19944883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No mental health without physical health.
    Tiihonen J; Lönnqvist J; Wahlbeck K; Klaukka T; Niskanen L; Tanskanen A; Haukka J
    Lancet; 2011 Feb; 377(9766):611. PubMed ID: 21334517
    [No Abstract]   [Full Text] [Related]  

  • 12. Medication-induced weight gain and dyslipidemia in patients with schizophrenia.
    Fenton WS; Chavez MR
    Am J Psychiatry; 2006 Oct; 163(10):1697-704; quiz 1858-9. PubMed ID: 17012676
    [No Abstract]   [Full Text] [Related]  

  • 13. Dyslipidemia and atypical antipsychotic drugs.
    Casey DE
    J Clin Psychiatry; 2004; 65 Suppl 18():27-35. PubMed ID: 15600382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological perspectives. Metabolic syndrome: schizophrenia and atypical antipsychotics.
    Keltner NL
    Perspect Psychiatr Care; 2006 Aug; 42(3):204-7. PubMed ID: 16916424
    [No Abstract]   [Full Text] [Related]  

  • 15. Metabolic risk during antipsychotic treatment.
    Newcomer JW
    Clin Ther; 2004 Dec; 26(12):1936-46. PubMed ID: 15823759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic effects of treatment with atypical antipsychotics.
    Kane JM; Barrett EJ; Casey DE; Correll CU; Gelenberg AJ; Klein S; Newcomer JW
    J Clin Psychiatry; 2004 Nov; 65(11):1447-55. PubMed ID: 15554755
    [No Abstract]   [Full Text] [Related]  

  • 17. When essential medications provoke new health problems: the metabolic effects of second-generation antipsychotics.
    Stein K
    J Am Diet Assoc; 2010 Jul; 110(7):992-1001. PubMed ID: 20630154
    [No Abstract]   [Full Text] [Related]  

  • 18. Obesity in adults with serious and persistent mental illness: a review of postulated mechanisms and current interventions.
    Megna JL; Schwartz TL; Siddiqui UA; Herrera Rojas M
    Ann Clin Psychiatry; 2011 May; 23(2):131-40. PubMed ID: 21547274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular aspects of antipsychotics.
    Raedler TJ
    Curr Opin Psychiatry; 2010 Nov; 23(6):574-81. PubMed ID: 20838345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can metformin or rosiglitazone reduce metabolic side effects associated with atypical antipsychotics?
    Housel AK; Waterbury N; Argo TR
    Issues Ment Health Nurs; 2009 Dec; 30(12):803-5. PubMed ID: 19916816
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.